Novartis

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Novartis and other ETFs, options, and stocks.

About NVS

Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. Its product portfolio is heavily focused on innovative prescription medicines, especially oncology, immunology, neuroscience, and cardiovascular diseases, supplemented by established older brands and a wide range of specialized therapies. 

CEO
Vasant Narasimhan
CEOVasant Narasimhan
Employees
75,267
Employees75,267
Headquarters
Basel, Basel-Stadt (Basle Town)
HeadquartersBasel, Basel-Stadt (Basle Town)
Founded
1996
Founded1996
Employees
75,267
Employees75,267

NVS Key Statistics

Market cap
282.14B
Market cap282.14B
Price-Earnings ratio
20.79
Price-Earnings ratio20.79
Dividend yield
2.22%
Dividend yield2.22%
Average volume
3.28M
Average volume3.28M
High today
High today
Low today
Low today
Open price
$140.58
Open price$140.58
Volume
4.16K
Volume4.16K
52 Week high
$170.46
52 Week high$170.46
52 Week low
$121.57
52 Week low$121.57

NVS News

Reuters 18h
Novartis halts ALS drug development after mid-stage trial failure - Reuters

...

Novartis halts ALS drug development after mid-stage trial failure - Reuters
Investor's Business Daily 20h
Novartis Suffers Another Setback After Two High-Profile Surprises Hammered Shares

Technology Novartis Suffers Another Setback After Two High-Profile Surprises Hammered Shares Licensing Novartis (NVS) added another failure to its docket Wednes...

Novartis Suffers Another Setback After Two High-Profile Surprises Hammered Shares
Seeking Alpha 22h
Novartis scraps ALS therapy after mid-stage trial setback

Novartis (NVS) has discontinued the development of VHB937/lifonebart, an experimental therapy for a fatal nervous system disease known as amyotrophic lateral sc...

Novartis scraps ALS therapy after mid-stage trial setback

Analyst ratings

53%

of 30 ratings
Buy
36.7%
Hold
53.3%
Sell
10%

More NVS News

Nasdaq 2d
Broker Darlings of the Dow: Johnson & Johnson Ranks As a Top 15 Analyst Pick

A study of analyst recommendations at the major brokerages shows that Johnson & Johnson (Symbol: JNJ) is the #10 broker pick, on average, out of the 30 stocks m...

Broker Darlings of the Dow: Johnson & Johnson Ranks As a Top 15 Analyst Pick
Nasdaq 3d
Novartis Just Shook Up a Multibillion-Dollar Drug Race. What It Means for Eli Lilly Stock.

Key Points Novartis recently announced bad news for its Lp(a)-lowering drug, pelacarsen. Lilly is also developing a therapy for lowering Lp(a). However, Nova...

Novartis Just Shook Up a Multibillion-Dollar Drug Race. What It Means for Eli Lilly Stock.
Benzinga 6d
Top Investor Urges Novartis for Stronger Acquisition Oversight After M&A and Trial Setbacks

A top investor in Novartis AG (NYSE:NVS) is reportedly urging a major board shake-up at the Swiss drugmaker to strengthen corporate governance after its stock s...

Top Investor Urges Novartis for Stronger Acquisition Oversight After M&A and Trial Setbacks
TipRanks 6d
Novartis investors to increase scrutiny of company’s strategy, Reuters reports

Novartis (NVS) investors will be increasing their scrutiny of the company’s dealmaking strategy following setbacks to drugs acquired through mergers and acquisi...

TipRanks 7d
Novartis shareholder calls for board changes, Reuters reports

A major Novartis (NVS) shareholder is calling for board changes following successive clinical setbacks and concerns over the company’s acquisition track record,...

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.